Valpromide

drugbox
IUPAC_name = 2-propylpentanamide


width = 158
CAS_number = 2430-27-5
ATC_prefix = N03
ATC_suffix = AG02
ATC_supplemental =
PubChem = 71113
DrugBank = EXPT03231
C = 8 | H = 17 | N = 1 | O = 1
molecular_weight = 143.228 g/mol
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
pregnancy_category =
legal_status =
routes_of_administration =

Valpromide (marketed as Depamide by sanofi-aventis) is a carboxamide derivative of valproic acid used in the treatment of epilepsy and some affective disorders. It is rapidly metabolised (80%) to valproic acid (another anticonvulsant) but has anticonvulsant properties itself. It may produce more stable plasma levels than valproic acid or sodium valproate and may be more effectively at preventing febrile seizures. However it is over one hundred times more potent inhibitor of liver microsomal epoxide hydrolase. This makes it incompatible with carbamazepine and can affect the ability of the body to remove other toxins. Valpromide is no safer during pregnancy than valproic acid.

Valpromide is formed through the reaction of valproic acid and ammonia via an intermediate acid chloride.

In pure form, valpromide is a white crystalline powder and has melting point 125-126°C. It is practically insoluble in water but soluble in hot water. It is available on the market in some European countries.

References

* "The Medical Treatment of Epilepsy" by Stanley R Resor. Published by Marcel Dekker (1991). ISBN 0-8247-8549-5.
* "Hydrolysis in Drug and Prodrug Metabolism: Chemistry, Biochemistry, and Enzymology" by Bernard Testa, Joachim M. Mayer (2003). ISBN 3-906390-25-X.
* "In Vitro Methods in Developmental Toxicology" by Gary L Kimmel, Devendra M Kochhar, Baumann (1989). ISBN 0-8493-6919-3.
* [http://www.psychotropics.dk/usr_view_molecule.asp?ID=2375&backurl=Alphaindex%2Fview%5Falpha%2Easp%3FStartchar%3DD&backurlname=Alphabetical+index&historyline=&Catalogtype=A The Lundbeck Institute Guide to Psychotropics - Valpromide]